Skip to main
RCEL

RCEL Stock Forecast & Price Target

RCEL Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AVITA Medical is on track for long term success as evidenced by the stabilizing and broadening growth of its single product, the RECELL system, in addition to its expanding global presence and positive clinical trial results for its Cohealyx product. With strong financial metrics, including a significant increase in guidance, and a favorable risk/reward, AVITA Medical is a strong investment option in the medical industry. However, potential risks such as regulatory and legal factors, as well as competition in the market, should be carefully considered.

Bears say

AVITA Medical is a high-risk investment due to its heavy reliance on a single product, the RECELL system, for its revenue. Despite FDA approval and acceptance in US burn centers, the company has not been able to successfully market the product globally, leading to limited sales and an overall negative outlook for future growth and profitability. Furthermore, the company's contract with BARDA for rapid deployment in burn mass casualty incidents may provide short-term revenue, but the majority of the $25.5M is discretionary and subject to BARDA's exercise, creating additional uncertainty for investors.

RCEL has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AVITA Medical Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AVITA Medical Inc (RCEL) Forecast

Analysts have given RCEL a Strong Buy based on their latest research and market trends.

According to 4 analysts, RCEL has a Strong Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AVITA Medical Inc (RCEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.